亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

医学 杜皮鲁玛 特应性皮炎 安慰剂 随机对照试验 内科学 皮肤病科 双盲 病理 替代医学
作者
Yan Ping Zhao,Liming Wu,Qianjin Lu,Xing‐Hua Gao,Xiaohong Zhu,Xu Yao,Linfeng Li,Wei Li,Yangfeng Ding,Zhiqiang Song,L. Liu,Ningning Dang,C Zhang,X. Liu,Jie Gu,J. Wang,Songmei Geng,Q. Liu,Yong Xia Guo,Li Dong
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:186 (4): 633-641 被引量:76
标识
DOI:10.1111/bjd.20690
摘要

BACKGROUND: Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD. METHODS: In this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300 mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both an Investigator's Global Assessment score of 0-1 and a reduction from baseline of ≥ 2 points at week 16. RESULTS: Overall, 165 patients (mean age 30·6 years; 71·5% male patients) were randomized; 82 patients were randomized to dupilumab and 83 patients were randomized to placebo. At week 16, 26·8% of patients in the dupilumab group and 4·8% of patients in the placebo group achieved the primary endpoint [difference 22·0%, 95% confidence interval (CI) 11·37-32·65; P < 0·001]. Compared with placebo, higher proportions of patients in the dupilumab group achieved ≥ 75% reduction in the Eczema Area and Severity Index score (57·3% vs. 14·5%; difference 42·9%, 95% CI 29·75-55·97; P < 0·001) and had ≥ 3-point (52·4% vs. 9·6%; difference 42·8%, 95% CI 30·26-55·34; P < 0·001) and ≥ 4-point (39·0% vs. 4·8%; difference 34·2%, 95% CI 22·69-45·72; P < 0·001) reductions in weekly average daily peak daily pruritus numerical rating scale scores. The incidence of treatment-emergent adverse events during the treatment period was similar in the two groups. The incidence of conjunctivitis, allergic conjunctivitis and injection site reaction was higher in the dupilumab group than in the placebo group. CONCLUSIONS: In adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favourable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
13秒前
43秒前
鱼鱼完成签到 ,获得积分10
46秒前
满意的伊完成签到,获得积分10
1分钟前
1分钟前
1分钟前
童严柯发布了新的文献求助10
1分钟前
1分钟前
ZZN发布了新的文献求助10
1分钟前
科研通AI2S的应助被yizhiyang采纳,获得10
1分钟前
佳佳发布了新的文献求助20
1分钟前
null的应助被ww采纳,获得10
1分钟前
童严柯发布了新的文献求助10
1分钟前
1分钟前
yizhiyang发布了新的文献求助10
1分钟前
1分钟前
杨飒完成签到,获得积分10
2分钟前
童严柯发布了新的文献求助10
2分钟前
万能图书馆的应助被yuyanzhang采纳,获得10
2分钟前
烟花的应助被科研通管家采纳,获得10
3分钟前
3分钟前
3分钟前
3分钟前
sugar发布了新的文献求助10
3分钟前
yuyanzhang发布了新的文献求助10
3分钟前
童严柯发布了新的文献求助10
3分钟前
ZZN完成签到,获得积分10
3分钟前
3分钟前
水北完成签到,获得积分10
3分钟前
3分钟前
佳佳发布了新的文献求助10
3分钟前
4分钟前
heluoyu完成签到,获得积分10
4分钟前
balko完成签到,获得积分10
4分钟前
传统完成签到,获得积分10
4分钟前
852的应助被sugar采纳,获得10
4分钟前
领导范儿的应助被mc采纳,获得10
4分钟前
4分钟前
哪块小饼干完成签到,获得积分10
4分钟前
dddj完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195136
求助须知:如何正确求助?哪些是违规求助? 9580891
关于积分的说明 21872931
捐赠科研通 7795122
什么是DOI,文献DOI怎么找? 3437934
关于科研通互助平台的介绍 2561241
邀请新用户注册赠送积分活动 2484641